Chester County News and Community Website
WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) said its subsidiary, HOPE Therapeutics, has begun treating patients using an artificial intelligence-guided transcranial magnetic stimulation system, a move the company says …
NRx Subsidiary Begins AI-Guided TMS Treatments in Florida Clinics Read More WILMINGTON, DE — NRx Pharmaceuticals (Nasdaq: NRXP) said the U.S. Food and Drug Administration has authorized an Expanded Access Protocol for its investigational depression treatment NRX-101, potentially allowing certain patients …
FDA Clears Expanded Access Path for NRx Depression Therapy Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) moved closer to potential commercialization of its preservative-free ketamine product in the first quarter as the company scaled manufacturing, advanced multiple FDA …
NRx Pushes Toward Ketamine Launch Amid FDA Review Read More WILMINGTON, DE — NRx Pharmaceuticals (Nasdaq: NRXP) received U.S. Food and Drug Administration clearance to begin a late-stage clinical trial evaluating whether its investigational NRX-101 therapy can improve outcomes for …
NRx Advances Depression Drug Study Targeting Military Use Read More WILMINGTON, DE — NRx Pharmaceuticals (Nasdaq: NRXP) has placed its first commercial manufacturing order for a preservative-free ketamine product ahead of a potential U.S. approval expected under the Generic Drug …
NRx Begins Ketamine Production Ahead of FDA Decision Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) recently received a Discipline Review Letter from the U.S. Food and Drug Administration identifying only minor administrative changes for its ketamine application …
NRx Reports FDA Feedback, Progress on Ketamine Application Read More WILMINGTON, DE — NRx Pharmaceuticals (Nasdaq: NRXP) said it supports an executive order signed April 18, 2026, directing federal agencies to accelerate research and regulatory pathways for treatments targeting serious …
NRx Pharmaceuticals Responds to Executive Order on Mental Health Treatments Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) recently appointed Glenn Tyson as its first chief commercial officer as the company prepares for anticipated regulatory milestones tied to its ketamine-based …
NRx Pharmaceuticals Appoints Glenn Tyson as Chief Commercial Officer Read More WILMINGTON, DE — NRx Pharmaceuticals Inc. (Nasdaq: NRXP) recently received preliminary feedback from the U.S. Food and Drug Administration on labeling for its preservative-free ketamine product, as the company continues …
NRx Receives FDA Feedback on Ketamine Drug Labeling Read More WILMINGTON, DE — NRx Pharmaceuticals Inc. (Nasdaq: NRXP) said the U.S. Food and Drug Administration has not identified bioequivalence deficiencies in its abbreviated new drug application for a preservative-free ketamine …
NRx Says FDA Finds No Bioequivalence Issues in Ketamine Filing Read More